COUR Pharmaceuticals Partners with Genentech in $940M Autoimmune Therapy Deal

Chicago-based biotech company COUR Pharmaceuticals has entered a significant collaboration with Roche's Genentech to develop and commercialize therapies for an undisclosed autoimmune disease. The deal, which is potentially worth more than $940 million, includes up to $40 million in upfront and immediate milestone payments, along with further potential payments exceeding $900 million and tiered royalties on net sales[1][2]. COUR will focus on preclinical development and technical transfer, while Genentech will oversee clinical development and marketing. This partnership is an extension of COUR’s continuous efforts to advance treatments in the autoimmune disease sector, leveraging its antigen-specific immune tolerance platform, which is designed to reprogram the immune system to address immune-mediated diseases from their roots[1][2].